Autry et al. showed that in mouse models of depression, ketamine promotes the rapid synthesis of brain-derived neurotrophic factor (BDNF) and p-mTOR that is known to have antidepressant effects, suggesting that this may provide a therapeutic target for developing fast-acting antidepressants [32]. This evidence concerns the gene BDNF and depressive symptom measurement.